Sanofi (SNY) fair value analysis
Nasdaq · Updated 2026-10-19
SNY price how computed
Valuation status
Reports in EURSNY reports its results in EUR while its shares trade in US dollars.
Forward Fair Value needs earnings and price in the same currency, so TickrTrends publishes no fair-value verdict for SNY until same-currency inputs are available. Price and market cap below are in US dollars; revenue and EPS are shown in EUR.
- Last price
- $40.67
- Sector
- Healthcare
- 12-month range
- $39.12–$52.34
- Market cap
- $97.5B
- From 52-week high
- -22.3%
- Shares outstanding
- 2.4B
- Rank in Healthcare by quality score
- #122 of 301
Last price is the 2026-10-01 month-start close, the freshest stored price; the chart runs through 2026-10-16.
Sanofi is a pharmaceutical company that researches, develops, manufactures, and distributes medicines and vaccines across multiple therapeutic areas including oncology, immunology, and infectious diseases. The company operates globally with a significant presence in Europe, North America, and other international markets.
SNY currently ranks #122 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
Revenue and EPS are shown in EUR; the trailing P/E is omitted because an EPS in EUR against a US-dollar share price would mislead.
- Market cap
- $97.5B
- Revenue (TTM)
- EUR 48.9B
- Net margin
- 8.1%
- EPS (TTM)
- EUR 4.91
- Gross margin
- 75.5%
- Debt / equity
- 0.34
- Revenue growth (3-yr avg)
- -1.0%
- Shares outstanding
- 2.4B
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Expanding
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 39 · neutral
- 50-day average
- $42.67
- 200-day average
- $44.63
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Dividends how computed
- Paid, last 12 months
- $2.42 per share (1 payment)
- Yield on last price
- 5.96%
- Consecutive years of increases
- 2
- Last ex-dividend date
- 2026-05-04
- Last payment date
- 2026-06-03
Earnings how computed
- Next earnings report
- 2026-10-30 (pre-market)
- Last 8 quarters vs consensus
- 6 beat, 2 missed
- Quarter by quarter
- 2026-06 ▲ beat (+10.0%)
2026-03 ▲ beat (+6.8%)
2025-12 ▲ beat (+7.1%)
2025-09 ▲ beat (+7.6%)
2025-06 ▼ miss (-9.0%)
2025-03 ▲ beat (+7.4%)
2024-12 ▼ miss (-8.1%)
2024-09 ▲ beat (+11.6%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 5 buy · 5 hold · 0 sell (10 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $53.6
- Target vs last price
- +31.8%
What our data shows for SNY
- Shares are trading in the lower third of their 12-month price range of $39.12–$52.34.
- The 14-day relative strength index sits at a neutral 39.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- SNY's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent SNY news
TickrTrends' derived news-sentiment signal for SNY is currently leaning positive, computed from recent coverage.
- Sanofi (SNY) Avoids EU Fine with Commitments on Vaccine Marketing Practices (gurufocus.com, 2026-10-14)
- European Commission Enforces Sanofi's Commitments on Antitrust Concerns (SNY) (gurufocus.com, 2026-10-14)
- Press Release : Availability of the aide-mémoire for Q3 2026 results (manilatimes.net, 2026-10-06)
More SNY news
- Sanofi: Stronger Launches And A New R&D Reset Keep The Re-Rating Case Alive (NASDAQ:SNY) (seekingalpha.com, 2026-09-16)
- Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines (manilatimes.net, 2026-09-14)
What people are saying
Follow the SNY conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for SNY showed a shift in momentum this week, with the RSI zone moving from oversold into neutral territory. The stock remains in the Healthcare sector with a valuation verdict of awaiting full valuation. This change reflects a moderation in short-term selling pressure compared to the prior week.
- 2026-10-05 — TickrTrends' derived indicators for SNY show a shift in trend momentum this week. The 50/200-day trend state has moved from mixed to downtrend, reflecting weaker near-term price performance relative to the longer-term trajectory. The stock's valuation verdict remains awaiting full valuation as of this assessment.
- 2026-09-28 — TickrTrends' derived indicators for SNY showed a shift this week as the relative strength index moved from neutral territory into oversold zone. The stock remains under a valuation verdict of awaiting full valuation as of this assessment. This technical reading suggests increased downward momentum in the healthcare sector holding.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — TickrTrends' valuation assessment for SNY shifted this week from Undervalued to awaiting full valuation, indicating that the derived indicators no longer support a clear undervaluation conclusion at this time. The change in verdict suggests that recent price movements or updated fundamental metrics have created a more ambiguous valuation picture for the healthcare sector company. Investors monitoring SNY should note that the stock's valuation status is currently pending a more complete analysis.
Frequently asked questions
Is SNY stock undervalued?
SNY reports its results in EUR while its shares trade in US dollars. Forward Fair Value needs earnings and price in the same currency, so TickrTrends publishes no fair-value verdict for SNY until same-currency inputs are available.
What is SNY's TickrTrends verdict?
SNY is currently marked 'Reports in EUR' - no verdict is published on inputs in two different currencies.
How does SNY compare to other Healthcare stocks?
SNY ranks #122 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is SNY overbought or oversold?
SNY's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does SNY pay a dividend?
Yes. SNY paid $2.42 per share over the last twelve months (1 payment), a 5.96% yield on TickrTrends' last price, and has raised the annual total for 2 consecutive years. The last ex-dividend date was 2026-05-04.
When does SNY report earnings next?
SNY's next earnings report is scheduled for 2026-10-30 (pre-market), per the published earnings calendar.
Does SNY usually beat earnings estimates?
Over its last 8 reported quarters SNY beat the consensus estimate 6 times and missed 2 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about SNY?
Of 10 analysts covering SNY, 5 rate it a buy, 5 a hold and 0 a sell - buy-leaning, with a consensus price target of $53.6 (+31.8% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.